



## **Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences**

May 14, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--May 14, 2018-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present at the following upcoming investor conferences:

- UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:30 AM ET. The conference is being held at the Grand Hyatt New York in New York City.
- Jefferies Global Healthcare Conference on Thursday, June 7, 2018 at 1:30 PM ET. The conference is being held at the Grand Hyatt New York in New York City.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at <https://investors.deciphera.com/news-events/events-presentations>. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

### About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry

library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180514005233/en/>

Source: Deciphera Pharmaceuticals, Inc.

Media:

The Yates Network

Gina Nugent, 617-460-3579

[gina@theyatesnetwork.com](mailto:gina@theyatesnetwork.com)

or

Investor Relations:

Argot Partners

Laura Perry, 212-600-1902

[Laura@argotpartners.com](mailto:Laura@argotpartners.com)

or

Sam Martin, 212-600-1902

[Sam@argotpartners.com](mailto:Sam@argotpartners.com)

or

Company:

Deciphera Pharmaceuticals, LLC

Christopher J. Morl, 781-209-6418

Chief Business Officer

[cmorl@deciphera.com](mailto:cmorl@deciphera.com)